The importance of inflammation burden ("inflammatory/pathogenic burden") for the cardiac aging.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2015
At a glance
- Drugs Fluvastatin (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Pharmacodynamics
- Acronyms Anti-CardAgeing
- 11 Oct 2014 Trial status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 18 Sep 2012 Planned End Date changed to 19 Apr 2012.
- 07 Jun 2012 New trial record